The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Acinetobacter Infections Treatment Market Research Report 2024
Synopsis
Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.
Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.
Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.
The global Acinetobacter Infections Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
In the American market, Major manufacturers include Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, and Legochem Biosciences, Atterx Biotherapeutics, Achaogen, Peptilogics, Sealife Pharma, Shionogi, Techulon and Tetraphase Pharmaceuticals, among others. Entasis Therapeutics, Roche and Adenium Biotech are the top 3 players of Acinetobacter Infections Treatment, with about 66% market shares.
This report aims to provide a comprehensive presentation of the global market for Acinetobacter Infections Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acinetobacter Infections Treatment.
Report Scope
The Acinetobacter Infections Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Acinetobacter Infections Treatment market comprehensively. Regional market sizes, concerning products by Type, by Pipeline, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acinetobacter Infections Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Pipeline, and by regions.
Market Segmentation
By Company
Entasis Therapeutics
Roche
Adenium Biotech
Vaxdyn
Hsiri Therapeutics
Aridis Pharmaceuticals
LegoChem Biosciences
Atterx Biotherapeutics
Achaogen
Peptilogics
Sealife PHARMA
Shionogi
Techulon
Tetraphase Pharmaceuticals
Segment by Type
Sulbactam
Carbapenems
Aminoglycosides
Polymyxins
Tetracyclines
Others
Segment by Pipeline
ETX2514
Nacubactam RG6080
Arenicin
VXD-001
Small Molecule Antibiotic
AR-401 mAB
LCB01-0371 (PO)
GN-4474
Antibacterial Antibody
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Pipeline, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acinetobacter Infections Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Pipeline, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.
Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.
Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.
The global Acinetobacter Infections Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
In the American market, Major manufacturers include Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, and Legochem Biosciences, Atterx Biotherapeutics, Achaogen, Peptilogics, Sealife Pharma, Shionogi, Techulon and Tetraphase Pharmaceuticals, among others. Entasis Therapeutics, Roche and Adenium Biotech are the top 3 players of Acinetobacter Infections Treatment, with about 66% market shares.
This report aims to provide a comprehensive presentation of the global market for Acinetobacter Infections Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acinetobacter Infections Treatment.
Report Scope
The Acinetobacter Infections Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Acinetobacter Infections Treatment market comprehensively. Regional market sizes, concerning products by Type, by Pipeline, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acinetobacter Infections Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Pipeline, and by regions.
Market Segmentation
By Company
Entasis Therapeutics
Roche
Adenium Biotech
Vaxdyn
Hsiri Therapeutics
Aridis Pharmaceuticals
LegoChem Biosciences
Atterx Biotherapeutics
Achaogen
Peptilogics
Sealife PHARMA
Shionogi
Techulon
Tetraphase Pharmaceuticals
Segment by Type
Sulbactam
Carbapenems
Aminoglycosides
Polymyxins
Tetracyclines
Others
Segment by Pipeline
ETX2514
Nacubactam RG6080
Arenicin
VXD-001
Small Molecule Antibiotic
AR-401 mAB
LCB01-0371 (PO)
GN-4474
Antibacterial Antibody
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Pipeline, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acinetobacter Infections Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Pipeline, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acinetobacter Infections Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Sulbactam
1.2.3 Carbapenems
1.2.4 Aminoglycosides
1.2.5 Polymyxins
1.2.6 Tetracyclines
1.2.7 Others
1.3 Market by Pipeline
1.3.1 Global Acinetobacter Infections Treatment Market Growth by Pipeline: 2019 VS 2023 VS 2030
1.3.2 ETX2514
1.3.3 Nacubactam RG6080
1.3.4 Arenicin
1.3.5 VXD-001
1.3.6 Small Molecule Antibiotic
1.3.7 AR-401 mAB
1.3.8 LCB01-0371 (PO)
1.3.9 GN-4474
1.3.10 Antibacterial Antibody
1.3.11 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Acinetobacter Infections Treatment Market Perspective (2019-2030)
2.2 Acinetobacter Infections Treatment Growth Trends by Region
2.2.1 Global Acinetobacter Infections Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Acinetobacter Infections Treatment Historic Market Size by Region (2019-2024)
2.2.3 Acinetobacter Infections Treatment Forecasted Market Size by Region (2025-2030)
2.3 Acinetobacter Infections Treatment Market Dynamics
2.3.1 Acinetobacter Infections Treatment Industry Trends
2.3.2 Acinetobacter Infections Treatment Market Drivers
2.3.3 Acinetobacter Infections Treatment Market Challenges
2.3.4 Acinetobacter Infections Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Acinetobacter Infections Treatment Players by Revenue
3.1.1 Global Top Acinetobacter Infections Treatment Players by Revenue (2019-2024)
3.1.2 Global Acinetobacter Infections Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Acinetobacter Infections Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Acinetobacter Infections Treatment Revenue
3.4 Global Acinetobacter Infections Treatment Market Concentration Ratio
3.4.1 Global Acinetobacter Infections Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acinetobacter Infections Treatment Revenue in 2023
3.5 Acinetobacter Infections Treatment Key Players Head office and Area Served
3.6 Key Players Acinetobacter Infections Treatment Product Solution and Service
3.7 Date of Enter into Acinetobacter Infections Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Acinetobacter Infections Treatment Breakdown Data by Type
4.1 Global Acinetobacter Infections Treatment Historic Market Size by Type (2019-2024)
4.2 Global Acinetobacter Infections Treatment Forecasted Market Size by Type (2025-2030)
5 Acinetobacter Infections Treatment Breakdown Data by Pipeline
5.1 Global Acinetobacter Infections Treatment Historic Market Size by Pipeline (2019-2024)
5.2 Global Acinetobacter Infections Treatment Forecasted Market Size by Pipeline (2025-2030)
6 North America
6.1 North America Acinetobacter Infections Treatment Market Size (2019-2030)
6.2 North America Acinetobacter Infections Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Acinetobacter Infections Treatment Market Size by Country (2019-2024)
6.4 North America Acinetobacter Infections Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Acinetobacter Infections Treatment Market Size (2019-2030)
7.2 Europe Acinetobacter Infections Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Acinetobacter Infections Treatment Market Size by Country (2019-2024)
7.4 Europe Acinetobacter Infections Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Acinetobacter Infections Treatment Market Size (2019-2030)
8.2 Asia-Pacific Acinetobacter Infections Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Acinetobacter Infections Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Acinetobacter Infections Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Acinetobacter Infections Treatment Market Size (2019-2030)
9.2 Latin America Acinetobacter Infections Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Acinetobacter Infections Treatment Market Size by Country (2019-2024)
9.4 Latin America Acinetobacter Infections Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Acinetobacter Infections Treatment Market Size (2019-2030)
10.2 Middle East & Africa Acinetobacter Infections Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Acinetobacter Infections Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Acinetobacter Infections Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Entasis Therapeutics
11.1.1 Entasis Therapeutics Company Detail
11.1.2 Entasis Therapeutics Business Overview
11.1.3 Entasis Therapeutics Acinetobacter Infections Treatment Introduction
11.1.4 Entasis Therapeutics Revenue in Acinetobacter Infections Treatment Business (2019-2024)
11.1.5 Entasis Therapeutics Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Acinetobacter Infections Treatment Introduction
11.2.4 Roche Revenue in Acinetobacter Infections Treatment Business (2019-2024)
11.2.5 Roche Recent Development
11.3 Adenium Biotech
11.3.1 Adenium Biotech Company Detail
11.3.2 Adenium Biotech Business Overview
11.3.3 Adenium Biotech Acinetobacter Infections Treatment Introduction
11.3.4 Adenium Biotech Revenue in Acinetobacter Infections Treatment Business (2019-2024)
11.3.5 Adenium Biotech Recent Development
11.4 Vaxdyn
11.4.1 Vaxdyn Company Detail
11.4.2 Vaxdyn Business Overview
11.4.3 Vaxdyn Acinetobacter Infections Treatment Introduction
11.4.4 Vaxdyn Revenue in Acinetobacter Infections Treatment Business (2019-2024)
11.4.5 Vaxdyn Recent Development
11.5 Hsiri Therapeutics
11.5.1 Hsiri Therapeutics Company Detail
11.5.2 Hsiri Therapeutics Business Overview
11.5.3 Hsiri Therapeutics Acinetobacter Infections Treatment Introduction
11.5.4 Hsiri Therapeutics Revenue in Acinetobacter Infections Treatment Business (2019-2024)
11.5.5 Hsiri Therapeutics Recent Development
11.6 Aridis Pharmaceuticals
11.6.1 Aridis Pharmaceuticals Company Detail
11.6.2 Aridis Pharmaceuticals Business Overview
11.6.3 Aridis Pharmaceuticals Acinetobacter Infections Treatment Introduction
11.6.4 Aridis Pharmaceuticals Revenue in Acinetobacter Infections Treatment Business (2019-2024)
11.6.5 Aridis Pharmaceuticals Recent Development
11.7 LegoChem Biosciences
11.7.1 LegoChem Biosciences Company Detail
11.7.2 LegoChem Biosciences Business Overview
11.7.3 LegoChem Biosciences Acinetobacter Infections Treatment Introduction
11.7.4 LegoChem Biosciences Revenue in Acinetobacter Infections Treatment Business (2019-2024)
11.7.5 LegoChem Biosciences Recent Development
11.8 Atterx Biotherapeutics
11.8.1 Atterx Biotherapeutics Company Detail
11.8.2 Atterx Biotherapeutics Business Overview
11.8.3 Atterx Biotherapeutics Acinetobacter Infections Treatment Introduction
11.8.4 Atterx Biotherapeutics Revenue in Acinetobacter Infections Treatment Business (2019-2024)
11.8.5 Atterx Biotherapeutics Recent Development
11.9 Achaogen
11.9.1 Achaogen Company Detail
11.9.2 Achaogen Business Overview
11.9.3 Achaogen Acinetobacter Infections Treatment Introduction
11.9.4 Achaogen Revenue in Acinetobacter Infections Treatment Business (2019-2024)
11.9.5 Achaogen Recent Development
11.10 Peptilogics
11.10.1 Peptilogics Company Detail
11.10.2 Peptilogics Business Overview
11.10.3 Peptilogics Acinetobacter Infections Treatment Introduction
11.10.4 Peptilogics Revenue in Acinetobacter Infections Treatment Business (2019-2024)
11.10.5 Peptilogics Recent Development
11.11 Sealife PHARMA
11.11.1 Sealife PHARMA Company Detail
11.11.2 Sealife PHARMA Business Overview
11.11.3 Sealife PHARMA Acinetobacter Infections Treatment Introduction
11.11.4 Sealife PHARMA Revenue in Acinetobacter Infections Treatment Business (2019-2024)
11.11.5 Sealife PHARMA Recent Development
11.12 Shionogi
11.12.1 Shionogi Company Detail
11.12.2 Shionogi Business Overview
11.12.3 Shionogi Acinetobacter Infections Treatment Introduction
11.12.4 Shionogi Revenue in Acinetobacter Infections Treatment Business (2019-2024)
11.12.5 Shionogi Recent Development
11.13 Techulon
11.13.1 Techulon Company Detail
11.13.2 Techulon Business Overview
11.13.3 Techulon Acinetobacter Infections Treatment Introduction
11.13.4 Techulon Revenue in Acinetobacter Infections Treatment Business (2019-2024)
11.13.5 Techulon Recent Development
11.14 Tetraphase Pharmaceuticals
11.14.1 Tetraphase Pharmaceuticals Company Detail
11.14.2 Tetraphase Pharmaceuticals Business Overview
11.14.3 Tetraphase Pharmaceuticals Acinetobacter Infections Treatment Introduction
11.14.4 Tetraphase Pharmaceuticals Revenue in Acinetobacter Infections Treatment Business (2019-2024)
11.14.5 Tetraphase Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
